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Equine infectious anemia virus (EIAV) is a retrovirus from genus Lentivirus that 
affects horses. The transmission of this virus occurs by blood-sucking insects of 
the genus Tabanidae, ingestion of secretions, excretions and contact with 
contaminated objects. Infected animals may present three stages of Equine 
infectious Anemia (EIA): acute, chronic and asymptomatic, with clinical signs 
varying from mild to death. The viral genome is composed of three main 
structures: gag, pol and env. The EIAV is a notifiable disease according to the 
International Animal Health Organization (OIE); in Brazil, euthanasia of infected 
animals is mandatory, except in the Pantanal region, an endemic area with a 
specific legislation. The gold standard diagnostic tests for EIA are AGID (Agar 
Gel Immunodiffusion) and ELISA (Enzyme Linked Immunosorbent Assay), but 
there are other tests that can contribute to the EIA diagnosis as, for example, 
viral isolation and molecular methods. However, studies have reported 
conflicting results between serological and molecular tests. Indications of this 
divergence may be related to variations in the viral envelope gp90 glycoproteins 
and gag p26 proteins. This work aimed to identify the variability of the p26 gene 
and protein to improve and develop new techniques and also clarify the 
molecular epidemiology of EIAV at the Pantanal region based on 35 blood 
plasma from affected horses. These samples were previously submitted to 
IDGA, ELISA, seminested and real-time PCR (qPCR) tests. Following, 24 
samples that presented positive results in serological and molecular tests were 
grouped separately from the remaining 11 samples which showed negative 
IDGA and/or ELISA and positive seminested and qPCR results. These two 
groups were submitted to nucleic acid extraction procedure and amplification of 
the gag region of the EIAV genomic DNA. After Sanger sequencing, the partial 
gag sequences were aligned and compared to the reference proteins BRA1 
(MN560970) and BRA2 (MN560971). The identity analysis of BRA1 in relation 
to sequences of this study ranged 86.24% to 93.61%, and BRA2 the variation 
was 87.66% to 99.57%.  Additionally, total of five known p26 protein linear 
epitopes were then compared based on the aligned amino acid sequences. This 
analysis showed no significative differences between the epitopes of the two 
groups of samples, therefore indicating these p26 protein segments are 
probably not determinant to the discrepancy observed between the serological 
and molecular tests results in one of the sample groups. So it can be inferred 
that these epitopes do not contribute to the modification of the protein, and 
probably other regions may induce some structural modification. Thus, a more 
detailed study is needed to elucidate the factors that interfere with the alteration 
of p26. 
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